Sarepta Therapeutics and Clinigen launch a managed access program to treat patients with Duchenne muscular dystrophy amenable to Exon 51 Skipping | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Sarepta Therapeutics and Clinigen launch a managed access program to treat patients with Duchenne muscular dystrophy amenable to Exon 51 Skipping


Sarepta Therapeutics, Inc., a U.S. biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, and Clinigen Group plc’s (AIM:CLIN) (‘Clinigen’) Idis Managed Access division, have initiated a Managed Access Program (MAP) for eteplirsen in certain geographies to treat eligible Duchenne muscular dystrophy (DMD) patients amenable to exon 51 skipping.

Sarepta Therapeutics And Clinigen Launch A Managed Access Program To Treat Patients With Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping